Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023

84%ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relapsed/refractory large B-cell lymphoma

Durable complete response was measured-68% at 1 month,61% at 3 months,and 60% at 6 months respectively.

DAEJEON,South Korea,June 20,2023 -- Curocell Inc,a Korea-based clinical-stage CAR-T cell therapy company,announced updated Phase 2 interim results for Anbalcabtagene-autoleucel (anbal-cel) on June 15,2023,at ICML (International Conference on Malignant Lymphoma),Lugano,Switzerland.

CUROCELL Inc.

The anbal-cel is the next-generation OVISTM technology applied to anti-CD19 CAR-T using the 4-1BB domain as a co-stimulation domain as and also it consists of a dual knockdown system for two immune checkpoint receptors,PD-1 and TIGIT,in CAR-T cells.

The Phase 2 study of anbal-cel was conducted to evaluate the efficacy and safety in patients with r/r LBCL. Patients with relapsed or refractory LBCL were enrolled in six Korean investigator sites to receive anbal-cel at a dose of 2x106CAR-T cells/kg.

41 patients with r/r LBCL were infused with anbal-cel. All patients received two or more prior lines of therapy and 10% (4 of 41) received ≥4 prior lines of treatment before the study.

84% ORR (32/38),71% CR (27/38) were reached,and durable complete response was monitored as CR at 1 month was 68% (26/38),CR at 3 months was 61% (19/31) and CR at 6 months was 60% (12/20) where median follow-up as 6.3 months.

Grade 3 CRS and ICANS were reported from 14.6% (6/41),and 7.3% (3/41) respectively. No grade 4 CRS and ICANS were observed. Prolonged neutropenia,cytopenia,and serious infection were observed in31.7% of patients (13/41),49% of patients (20/41),and 10% of patients (4/41) respectively.

Curocell is planning on submitting an NDA to MFDS in mid-2024 and recently completed the construction of the largest commercial GMP facility for CAR-T production in Daejeon,Korea.

About anbalcabtagene autoleucel (anbal-cel)

Anbal-cel,recognized CD19 and is based on OVIS™,a first-in-class CAR-T platform. OVIS™ technology downregulates PD1 and TIGIT expression on CAR-T cells. Through overcoming the immune suppression by PD-1 and TIGIT ligands,OVIS™ CAR-T has superior cytotoxicity to tumor cells in the tumor microenvironment. Anbal-cel is in a Phase II clinical trial in patients wit DLBCL in South Korea.

About Curocell

Curocell,based in Daejeon,is clinical-stage biotech innovating CAR-T therapies. Curocell is developing OVIS™ technology with the goal of improving the clinical efficacy of CAR-T therapies. Curocell is conducting a Phase II clinical trial of Anbal-cel in South Korea and is preparing to commercialize CAR-T therapies to bring innovative treatments to patients,including establishing the first and largest commercial GMP for CAR-T therapies in South Korea.

For more information,visit curocellbtx.com/en.

Details of the oral presentation at ICML are as follows:

Program and Abstract Book Nr. 45

Title: Phase 2 Study of Anbal-cel,Novel Anti-CD19 CAR-T therapy with Dual Silencing of PD-1 and TIGIT in Relapsed or Refractory Large B Cell Lymphoma-Interim Analysis Result

Session Title: New CAR-T cell Approaches

Session date and time: June 15,15:30-15:45

Venue: Palazzo dei Congressi,Lugano

Session room: Room B